Baseline clinical characteristics, angiographic, and procedural parameters in the study population (n = 126)
| . | STEMI-patients with subsequent ventricular arrhythmia, n = 21 . | STEMI-patients without subsequent ventricular arrhythmia, n = 105 . | P-value . |
|---|---|---|---|
| Age at STEMI, year | 58.0 ± 10.5 | 57.9 ± 8.5 | 0.78 |
| Male sex, n (%) | 19 (90) | 90 (86) | 0.54 |
| BSA, m2 (IQR) | 2.0 ± 0.2 | 2.0 ± 0.2 | 1.00 |
| Randomization, DANAMI, n (%): | |||
| ȃDEFER, deferred stenting | 4 (19) | 19 (18) | 0.92 |
| ȃiPOST, ischaemic post-conditioning | 4 (19) | 20 (19) | 1.00 |
| ȃPRIMULTI, complete | 6 (29) | 30 (29) | 1.00 |
| Randomization, Danegaptide, high, n (%) | 2 (10) | 11 (10) | 1.00 |
| Hypertension, n (%) | 7 (35) | 35 (33) | 0.84 |
| Diabetes, n (%) | 3 (14) | 6 (6) | 0.17 |
| Dyslipidaemia, n (%) | 7 (35) | 33 (31) | 0.71 |
| CKD, n (%) | 0 | 0 | |
| Smoking: | 0.42 | ||
| ȃFormer, n (%) | 5 (25) | 41 (39) | |
| ȃActive, n (%) | 13 (60) | 47 (45) | |
| Familiar IHD, n (%) | 12 (57) | 45 (43) | 0.24 |
| Known IHD, n (%) | 1 (5) | 2 (2) | 0.43 |
| Previous ischaemic stroke, n (%) | 1 (5) | 4 (4) | 0.85 |
| Known CHF, n (%) | 4 (21) | 23 (22) | 0.92 |
| Angiographic and procedural parameters, n (%): | |||
| ȃAnterior located infarction, | 10 (47) | 49 (47) | 0.92 |
| ȃLocation of culprit lesion: | 0.92 | ||
| ȃȃȃLAD | 10 (48) | 49 (47) | |
| ȃȃȃCx | 4 (19) | 17 (16) | |
| ȃȃȃRCA | 7 (33) | 39 (37) | |
| ȃCTO | 1 (5) | 7 (7) | 0.74 |
| ȃMVD | 6 (29) | 28 (27) | 0.86 |
| ȃComplete revascularization | 15 (71) | 77 (73) | 0.86 |
| Medications at discharge, n (%): | |||
| ȃAspirin | 20 (95) | 104 (99) | 0.20 |
| ȃTicagrelor | 5 (24) | 15 (14) | 0.28 |
| ȃPrasugrel | 15 (71) | 87 (83) | 0.22 |
| ȃClopidogrel | 0 | 2 (2) | 0.52 |
| ȃBeta-blocker | 16 (76) | 95 (90) | 0.10 |
| ȃACE or ARB | 11 (52) | 43 (41) | 0.33 |
| ȃStatin | 21 (100) | 105 (97) | 0.43 |
| . | STEMI-patients with subsequent ventricular arrhythmia, n = 21 . | STEMI-patients without subsequent ventricular arrhythmia, n = 105 . | P-value . |
|---|---|---|---|
| Age at STEMI, year | 58.0 ± 10.5 | 57.9 ± 8.5 | 0.78 |
| Male sex, n (%) | 19 (90) | 90 (86) | 0.54 |
| BSA, m2 (IQR) | 2.0 ± 0.2 | 2.0 ± 0.2 | 1.00 |
| Randomization, DANAMI, n (%): | |||
| ȃDEFER, deferred stenting | 4 (19) | 19 (18) | 0.92 |
| ȃiPOST, ischaemic post-conditioning | 4 (19) | 20 (19) | 1.00 |
| ȃPRIMULTI, complete | 6 (29) | 30 (29) | 1.00 |
| Randomization, Danegaptide, high, n (%) | 2 (10) | 11 (10) | 1.00 |
| Hypertension, n (%) | 7 (35) | 35 (33) | 0.84 |
| Diabetes, n (%) | 3 (14) | 6 (6) | 0.17 |
| Dyslipidaemia, n (%) | 7 (35) | 33 (31) | 0.71 |
| CKD, n (%) | 0 | 0 | |
| Smoking: | 0.42 | ||
| ȃFormer, n (%) | 5 (25) | 41 (39) | |
| ȃActive, n (%) | 13 (60) | 47 (45) | |
| Familiar IHD, n (%) | 12 (57) | 45 (43) | 0.24 |
| Known IHD, n (%) | 1 (5) | 2 (2) | 0.43 |
| Previous ischaemic stroke, n (%) | 1 (5) | 4 (4) | 0.85 |
| Known CHF, n (%) | 4 (21) | 23 (22) | 0.92 |
| Angiographic and procedural parameters, n (%): | |||
| ȃAnterior located infarction, | 10 (47) | 49 (47) | 0.92 |
| ȃLocation of culprit lesion: | 0.92 | ||
| ȃȃȃLAD | 10 (48) | 49 (47) | |
| ȃȃȃCx | 4 (19) | 17 (16) | |
| ȃȃȃRCA | 7 (33) | 39 (37) | |
| ȃCTO | 1 (5) | 7 (7) | 0.74 |
| ȃMVD | 6 (29) | 28 (27) | 0.86 |
| ȃComplete revascularization | 15 (71) | 77 (73) | 0.86 |
| Medications at discharge, n (%): | |||
| ȃAspirin | 20 (95) | 104 (99) | 0.20 |
| ȃTicagrelor | 5 (24) | 15 (14) | 0.28 |
| ȃPrasugrel | 15 (71) | 87 (83) | 0.22 |
| ȃClopidogrel | 0 | 2 (2) | 0.52 |
| ȃBeta-blocker | 16 (76) | 95 (90) | 0.10 |
| ȃACE or ARB | 11 (52) | 43 (41) | 0.33 |
| ȃStatin | 21 (100) | 105 (97) | 0.43 |
Data are presented as mean ± standard deviation for continuous variables and number and percentages for categorical variables. Missing: smoking (2%); diabetes (1%), dyslipidaemia (2%); CKD (23%); familiar IHD (2%); known IHD (10%); previous ischaemic stroke (1%); echocardiographic LVEF at follow-up (8%); CHF (10%); statin (1%).
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BSA, body surface area; CKD, chronic kidney disease; CHF, chronic heart failure; CTO, chronic total occlusion; Cx, circumflex artery; DANAMI, DANish Acute Myocardial Infarction; DEFER, deferred stenting vs. conventional primary percutaneous coronary intervention; IHD, ischaemic heart disease; iPOST, ischaemic post-conditioning vs. conventional primary percutaneous intervention; IQR, interquartile range; LAD, left anterior descending artery; LVEF, left ventricular ejection fraction; MVD, multi-vessel disease; PRIMULTI, complete vs. culprit lesion only revascularization; RCA, right coronary artery; STEMI, ST-segment elevation myocardial infarction.
Baseline clinical characteristics, angiographic, and procedural parameters in the study population (n = 126)
| . | STEMI-patients with subsequent ventricular arrhythmia, n = 21 . | STEMI-patients without subsequent ventricular arrhythmia, n = 105 . | P-value . |
|---|---|---|---|
| Age at STEMI, year | 58.0 ± 10.5 | 57.9 ± 8.5 | 0.78 |
| Male sex, n (%) | 19 (90) | 90 (86) | 0.54 |
| BSA, m2 (IQR) | 2.0 ± 0.2 | 2.0 ± 0.2 | 1.00 |
| Randomization, DANAMI, n (%): | |||
| ȃDEFER, deferred stenting | 4 (19) | 19 (18) | 0.92 |
| ȃiPOST, ischaemic post-conditioning | 4 (19) | 20 (19) | 1.00 |
| ȃPRIMULTI, complete | 6 (29) | 30 (29) | 1.00 |
| Randomization, Danegaptide, high, n (%) | 2 (10) | 11 (10) | 1.00 |
| Hypertension, n (%) | 7 (35) | 35 (33) | 0.84 |
| Diabetes, n (%) | 3 (14) | 6 (6) | 0.17 |
| Dyslipidaemia, n (%) | 7 (35) | 33 (31) | 0.71 |
| CKD, n (%) | 0 | 0 | |
| Smoking: | 0.42 | ||
| ȃFormer, n (%) | 5 (25) | 41 (39) | |
| ȃActive, n (%) | 13 (60) | 47 (45) | |
| Familiar IHD, n (%) | 12 (57) | 45 (43) | 0.24 |
| Known IHD, n (%) | 1 (5) | 2 (2) | 0.43 |
| Previous ischaemic stroke, n (%) | 1 (5) | 4 (4) | 0.85 |
| Known CHF, n (%) | 4 (21) | 23 (22) | 0.92 |
| Angiographic and procedural parameters, n (%): | |||
| ȃAnterior located infarction, | 10 (47) | 49 (47) | 0.92 |
| ȃLocation of culprit lesion: | 0.92 | ||
| ȃȃȃLAD | 10 (48) | 49 (47) | |
| ȃȃȃCx | 4 (19) | 17 (16) | |
| ȃȃȃRCA | 7 (33) | 39 (37) | |
| ȃCTO | 1 (5) | 7 (7) | 0.74 |
| ȃMVD | 6 (29) | 28 (27) | 0.86 |
| ȃComplete revascularization | 15 (71) | 77 (73) | 0.86 |
| Medications at discharge, n (%): | |||
| ȃAspirin | 20 (95) | 104 (99) | 0.20 |
| ȃTicagrelor | 5 (24) | 15 (14) | 0.28 |
| ȃPrasugrel | 15 (71) | 87 (83) | 0.22 |
| ȃClopidogrel | 0 | 2 (2) | 0.52 |
| ȃBeta-blocker | 16 (76) | 95 (90) | 0.10 |
| ȃACE or ARB | 11 (52) | 43 (41) | 0.33 |
| ȃStatin | 21 (100) | 105 (97) | 0.43 |
| . | STEMI-patients with subsequent ventricular arrhythmia, n = 21 . | STEMI-patients without subsequent ventricular arrhythmia, n = 105 . | P-value . |
|---|---|---|---|
| Age at STEMI, year | 58.0 ± 10.5 | 57.9 ± 8.5 | 0.78 |
| Male sex, n (%) | 19 (90) | 90 (86) | 0.54 |
| BSA, m2 (IQR) | 2.0 ± 0.2 | 2.0 ± 0.2 | 1.00 |
| Randomization, DANAMI, n (%): | |||
| ȃDEFER, deferred stenting | 4 (19) | 19 (18) | 0.92 |
| ȃiPOST, ischaemic post-conditioning | 4 (19) | 20 (19) | 1.00 |
| ȃPRIMULTI, complete | 6 (29) | 30 (29) | 1.00 |
| Randomization, Danegaptide, high, n (%) | 2 (10) | 11 (10) | 1.00 |
| Hypertension, n (%) | 7 (35) | 35 (33) | 0.84 |
| Diabetes, n (%) | 3 (14) | 6 (6) | 0.17 |
| Dyslipidaemia, n (%) | 7 (35) | 33 (31) | 0.71 |
| CKD, n (%) | 0 | 0 | |
| Smoking: | 0.42 | ||
| ȃFormer, n (%) | 5 (25) | 41 (39) | |
| ȃActive, n (%) | 13 (60) | 47 (45) | |
| Familiar IHD, n (%) | 12 (57) | 45 (43) | 0.24 |
| Known IHD, n (%) | 1 (5) | 2 (2) | 0.43 |
| Previous ischaemic stroke, n (%) | 1 (5) | 4 (4) | 0.85 |
| Known CHF, n (%) | 4 (21) | 23 (22) | 0.92 |
| Angiographic and procedural parameters, n (%): | |||
| ȃAnterior located infarction, | 10 (47) | 49 (47) | 0.92 |
| ȃLocation of culprit lesion: | 0.92 | ||
| ȃȃȃLAD | 10 (48) | 49 (47) | |
| ȃȃȃCx | 4 (19) | 17 (16) | |
| ȃȃȃRCA | 7 (33) | 39 (37) | |
| ȃCTO | 1 (5) | 7 (7) | 0.74 |
| ȃMVD | 6 (29) | 28 (27) | 0.86 |
| ȃComplete revascularization | 15 (71) | 77 (73) | 0.86 |
| Medications at discharge, n (%): | |||
| ȃAspirin | 20 (95) | 104 (99) | 0.20 |
| ȃTicagrelor | 5 (24) | 15 (14) | 0.28 |
| ȃPrasugrel | 15 (71) | 87 (83) | 0.22 |
| ȃClopidogrel | 0 | 2 (2) | 0.52 |
| ȃBeta-blocker | 16 (76) | 95 (90) | 0.10 |
| ȃACE or ARB | 11 (52) | 43 (41) | 0.33 |
| ȃStatin | 21 (100) | 105 (97) | 0.43 |
Data are presented as mean ± standard deviation for continuous variables and number and percentages for categorical variables. Missing: smoking (2%); diabetes (1%), dyslipidaemia (2%); CKD (23%); familiar IHD (2%); known IHD (10%); previous ischaemic stroke (1%); echocardiographic LVEF at follow-up (8%); CHF (10%); statin (1%).
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BSA, body surface area; CKD, chronic kidney disease; CHF, chronic heart failure; CTO, chronic total occlusion; Cx, circumflex artery; DANAMI, DANish Acute Myocardial Infarction; DEFER, deferred stenting vs. conventional primary percutaneous coronary intervention; IHD, ischaemic heart disease; iPOST, ischaemic post-conditioning vs. conventional primary percutaneous intervention; IQR, interquartile range; LAD, left anterior descending artery; LVEF, left ventricular ejection fraction; MVD, multi-vessel disease; PRIMULTI, complete vs. culprit lesion only revascularization; RCA, right coronary artery; STEMI, ST-segment elevation myocardial infarction.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
